Last reviewed · How we verify
Binge Eating Liraglutide Intervention (BELIEVE)
The study is a 17-week, single-center, double-blind, parallel-group, randomized placebo controlled trial that will test the efficacy of liraglutide 3.0 mg/d as compared to placebo in reducing the number of binge episodes per week, achieving remission from binge episodes, and in changes in body weight, global BED symptom improvement, cognitive restraint of food intake, dietary disinhibition, perceived hunger, quality of life, and depressed mood at treatment end.
Details
| Lead sponsor | Kelly Allison |
|---|---|
| Phase | PHASE3 |
| Status | TERMINATED |
| Enrolment | 36 |
| Start date | Fri Sep 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Binge-Eating Disorder
Interventions
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
- Placebo
Countries
United States